TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Seattle-based Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing its total financing to $16 million. The startup says it will use the money to expand its virtual home-care program nationwide and aims to reach tens of thousands of patients within two years; its cost-savings and clinical impact figures are company claims.
Seattle-based Kivo Health has raised $10 million in Series A financing to expand its virtual home-care service nationwide, which currently focuses on people with chronic obstructive pulmonary disease (COPD). The round, led by Allumia Ventures, brings the company’s reported total financing to $16 million as it seeks to make ongoing respiratory support available to more patients outside clinic visits.
Other investors in the round include Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures. Kivo says the financing will support nationwide growth and expansion of its care model to other high-cost chronic illnesses. The company has not disclosed how the funding will be allocated among hiring, technology, marketing or other expenses.
Kivo’s current program combines home-use equipment and virtual respiratory therapy. After enrollment, patients receive a kit that includes a tablet, an oxygen monitor and exercise bands. They meet virtually with a respiratory therapist for an assessment and an individualized plan, then take part in twice-weekly small-group sessions for nine weeks, according to the company’s website. Sessions cover breathing techniques, targeted exercise and information about managing COPD.
Co-founder and CEO Victor Sadauskas told Home Health Care News by email that Kivo has delivered tens of thousands of sessions and provided care to thousands of patients. He said the company plans to expand nationwide and serve tens of thousands of patients over the next two years. Kivo says its program is covered by Medicare, Medicaid and several commercial insurers, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health.
Funding Targets Wider COPD Access
The financing gives Kivo capital to extend a care model built around remote support between clinical visits. For people managing COPD, a chronic lung disease, access to respiratory therapists and structured guidance at home may add another option alongside in-person care. The company’s stated expansion goal makes the round relevant to patients and health plans assessing how virtual services could fit into chronic-care programs.
Kivo also says its approach can reduce avoidable hospitalizations, emergency department visits and nursing home stays. It claims to lower total health care spending by $8,245 per member per year. That figure is a company-reported estimate; the source report does not provide the methodology, comparison group or time period behind it. The funding announcement does not independently establish clinical outcomes or savings.
Broader expansion will depend on more than financing: the company will need to reach eligible patients, work with health plans and deliver its program across additional markets. The announcement signals an intention to scale, but does not specify which states or patient groups will be added first.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
How Kivo’s Program Works
Kivo describes its service as AI-powered virtual home care for chronic lung disease, beginning with COPD. Its model pairs equipment used at home with contact with respiratory therapists and group-based sessions. The reported nine-week schedule is a defined course of support; the source material does not detail what follow-up care is available after the course ends.
The company says it has already delivered tens of thousands of sessions and reached thousands of patients. Those figures, along with its statements about improved symptoms and reduced use of hospitals and other services, come from Kivo and were reported by Home Health Care News. They are not presented in the source as results from an independently reviewed study.
“We plan to expand nationwide to deliver care to tens of thousands of patients in the next two years.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion Plans and Savings Evidence
Kivo has not specified the markets it will enter first, the timing of individual launches or how the $10 million will be spent. Its goal of serving tens of thousands of patients within two years is a forward-looking target, and the announcement does not identify a starting patient count or define the precise measure of reach.
The evidence supporting the company’s claims about symptom improvement and avoided hospitalizations is also not detailed in the source report. Kivo’s estimate of $8,245 in annual savings per member is not accompanied there by a description of its calculation, comparison baseline or evaluation period. It remains unclear how those results vary across patients or health plans, and whether independent research has assessed them.
National Rollout Over Two Years
Kivo says it plans to use the new financing to expand nationwide and aims to provide care to tens of thousands of patients in the next two years. The company has also said it intends to adapt its care model for other high-cost chronic illnesses, but has not named the conditions or set a timetable for those programs.
Further details to watch include where Kivo launches next, how its insurer coverage changes as it grows and whether it publishes more information about patient outcomes and health care savings. The funding announcement establishes the company’s expansion plans, but the rollout and results have yet to be reported.
Key Questions
How much funding did Kivo Health raise?
Kivo raised $10 million in a Series A round, led by Allumia Ventures. The company’s reported total financing is now $16 million.
What does Kivo Health’s virtual care program provide?
Its current program focuses on COPD. Patients receive a home kit with a tablet, oxygen monitor and exercise bands, and meet virtually with a respiratory therapist. The company describes a nine-week course with twice-weekly small-group sessions.
Which investors participated in the Series A?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated, according to the report.
What does Kivo plan to do with the funding?
Kivo says it will support a nationwide expansion and aims to reach tens of thousands of patients within two years. It also intends to adapt its model for other high-cost chronic illnesses, though it has not named those conditions.
Are Kivo’s reported savings independently verified?
The source report attributes to Kivo a claim of $8,245 in lower annual health care spending per member. It does not provide the calculation method, comparison baseline or evaluation period, so the figure cannot be assessed from the information reported.
Source: homehealthcarenews.com
